Brand Name

Anthim

Generic Name
Obiltoxaximab
View Brand Information
FDA approval date: March 18, 2016
Classification: Anthrax Protective Antigen-directed Antibody
Form: Solution

What is Anthim (Obiltoxaximab)?

ANTHIM ® is a monoclonal antibody directed against the protective antigen of Bacillus anthracis. It is indicated in adult and pediatric patients for treatment of inhalational anthrax due to B. anthracis in combination with appropriate antibacterial drugs and, for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

Approved To Treat

Top Global Experts

There are no experts for this drug

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Welder's Anthrax Treated with Obiltoxaximab - Louisiana, 2024.
Welder's Anthrax Treated with Obiltoxaximab - Louisiana, 2024.
Journal: MMWR. Morbidity and mortality weekly report
Published: December 30, 2025
Use of animal efficacy, pharmacokinetic/pharmacodynamic and first in human data for regulatory approval of treatment options against chemical, biological, radiological and nuclear threats.
Use of animal efficacy, pharmacokinetic/pharmacodynamic and first in human data for regulatory approval of treatment options against chemical, biological, radiological and nuclear threats.
Journal: Philosophical transactions of the Royal Society of London. Series B, Biological sciences
Published: January 31, 2025
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism.
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism.
Journal: Expert opinion on drug safety
Published: August 18, 2023
View All Latest Advances